Interleukin 6 Receptor

The interluekin-6 receptor (IL-6R) is the receptor that IL-6 binds to in order to initiate the body’s responses to inflammation and infection.

In what is referred to as “classical signalling”, IL-6 exerts its effects by binding to IL-6R, a glycosylated type 1 membrane-bound protein of around 80 kDa. This binding is mediated by domain 2 and 3 residues on IL-6R. Upon ligand binding, IL-6R associates with a signalling receptor protein called gp130, which then undergoes dimerization.

This leads to the activation of Junase kinases and the phosphorylation of tyrosine residues within gp130 and events that activate the ras/raf/Mitogen-activated protein (MAP) kinase (MAPK) pathway.

Signal transducer and activator of transcription (STAT) factors are also recruited, which undergo phosphorylation, dimerize and then move into the nucleus to activate target genes.

Only a small number of cells express this membrane-bound IL-6R and can therefore respond to IL-6 alone. Examples include neutrophils, macrophages, hepatocytes and some types of T cells. Gp130, on the other hand, is expressed on the surface of all cells. Cells that only express gp130 do not respond to IL-6 alone. However, these cells do respond if IL-6 is bound in a complex to the soluble form of IL-6R (sIL-6R).

Generation of sIL-6R therefore dramatically increases the range of cells that can be targeted and activated by IL-6. This activation of cells by the IL-6/sIL-6R complex is referred to as “trans-signalling.”

The sIL-6R is formed through proteolytic cleavage of the precursor IL-6R, which is carried out by membrane-bound metalloproteases of the ADAM (a disintegrin and metalloprotease) family. The sIL-6R binds IL-6 with a similar affinity to IL-6R. The IL-6/sIL-6R complex then mediates the activation of gp130 in either an autocrine or paracrine manner.

Trans-signalling activation of gp130 is essential for recruiting lymphocytes to areas of inflammation through the control of chemokine expression. This IL-6 trans-signalling also promotes the proliferation of T cells and regulates the expression of adhesion molecules on endothelial cells.

Further Reading

Last Updated: Aug 23, 2018

Sally Robertson

Written by

Sally Robertson

Sally has a Bachelor's Degree in Biomedical Sciences (B.Sc.). She is a specialist in reviewing and summarising the latest findings across all areas of medicine covered in major, high-impact, world-leading international medical journals, international press conferences and bulletins from governmental agencies and regulatory bodies. At News-Medical, Sally generates daily news features, life science articles and interview coverage.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2018, August 23). Interleukin 6 Receptor. News-Medical. Retrieved on June 17, 2019 from https://www.news-medical.net/health/Interleukin-6-Receptor.aspx.

  • MLA

    Robertson, Sally. "Interleukin 6 Receptor". News-Medical. 17 June 2019. <https://www.news-medical.net/health/Interleukin-6-Receptor.aspx>.

  • Chicago

    Robertson, Sally. "Interleukin 6 Receptor". News-Medical. https://www.news-medical.net/health/Interleukin-6-Receptor.aspx. (accessed June 17, 2019).

  • Harvard

    Robertson, Sally. 2018. Interleukin 6 Receptor. News-Medical, viewed 17 June 2019, https://www.news-medical.net/health/Interleukin-6-Receptor.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post